- Home
- RXO vs REVBW Comparison
RXO vs REVBW Comparison
Compare RXO & REVBW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXO
- REVBW
- Stock Information
- Founded
- RXO 2022
- REVBW N/A
- Country
- RXO United States
- REVBW United States
- Employees
- RXO N/A
- REVBW 9
- Industry
- RXO
- REVBW Biotechnology: Pharmaceutical Preparations
- Sector
- RXO
- REVBW Health Care
- Exchange
- RXO Nasdaq
- REVBW Nasdaq
- Market Cap
- RXO N/A
- REVBW N/A
- IPO Year
- RXO N/A
- REVBW 2020
- Fundamental
- Price
- RXO $13.24
- REVBW N/A
- Analyst Decision
- RXO Hold
- REVBW
- Analyst Count
- RXO 17
- REVBW 0
- Target Price
- RXO $23.00
- REVBW N/A
- AVG Volume (30 Days)
- RXO 1.7M
- REVBW N/A
- Earning Date
- RXO 05-07-2025
- REVBW N/A
- Dividend Yield
- RXO N/A
- REVBW N/A
- EPS Growth
- RXO N/A
- REVBW N/A
- EPS
- RXO N/A
- REVBW N/A
- Revenue
- RXO $4,550,000,000.00
- REVBW N/A
- Revenue This Year
- RXO $45.19
- REVBW N/A
- Revenue Next Year
- RXO $7.98
- REVBW N/A
- P/E Ratio
- RXO N/A
- REVBW N/A
- Revenue Growth
- RXO 15.87
- REVBW N/A
- 52 Week Low
- RXO $12.39
- REVBW N/A
- 52 Week High
- RXO $32.82
- REVBW N/A
- Technical
- Relative Strength Index (RSI)
- RXO 31.98
- REVBW N/A
- Support Level
- RXO $12.70
- REVBW N/A
- Resistance Level
- RXO $14.33
- REVBW N/A
- Average True Range (ATR)
- RXO 1.35
- REVBW 0.00
- MACD
- RXO -0.21
- REVBW 0.00
- Stochastic Oscillator
- RXO 11.71
- REVBW 0.00
About REVBW Revelation Biosciences Inc. Warrant
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).